SYNBIOTIC SE Strengthens Strategic Position Amid Changes

SYNBIOTIC SE has undertaken significant strategic adjustments following a comprehensive review of its operations. The decision to discontinue financial support for its Austrian subsidiary, Bushdoctor GmbH, highlights a move to streamline its portfolio. This action aligns with a new focus on core areas, namely medical cannabis and industrial hemp, reducing expenses in the process.

Simultaneously, SYNBIOTIC has enhanced its financial standing through additional equity financing. Two recent capital increases raised approximately €0.64 million by issuing 387,000 new shares, albeit with a 5% dilution. This capital influx is set to bolster product development and operational initiatives.

The entrance of CANSOUL as a strategic investor further solidifies SYNBIOTIC’s position. CANSOUL's investment promises long-term partnership benefits, offering potential access to more capital and a vast industry network. Despite a downward adjustment in FY25 guidance due to regulatory hurdles, SYNBIOTIC aims for renewed growth, targeting €25 million in sales by FY27.